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Abstract
Background: It is increasingly clear that in addition to myelin disruption, axonal degeneration may also represent a
key pathology in multiple sclerosis (MS). Hence, elucidating the mechanisms of axonal degeneration may not only
enhance our understanding of the overall MS pathology, but also elucidate additional therapeutic targets. The
objective of this study is assess the degree of axonal membrane disruption and its significance in motor deficits in
EAE mice.
Methods: Experimental Autoimmune Encephalomyelitis was induced in mice by subcutaneous injection of myelin
oligodendrocyte glycoprotein/complete Freud’s adjuvant emulsion, followed by two intraperitoneal injections of
pertussis toxin. Behavioral assessment was performed using a 5-point scale. Horseradish Peroxidase Exclusion test
was used to quantify the disruption of axonal membrane. Polyethylene glycol was prepared as a 30% (w/v) solution
in phosphate buffered saline and injected intraperitoneally.
Results: We have found evidence of axonal membrane disruption in EAE mice when symptoms peak and to a lesser
degree, in the pre-symptomatic stage of EAE mice. Furthermore, polyethylene glycol (PEG), a known membrane
fusogen, significantly reduces axonal membrane disruption in EAE mice. Such PEG-mediated membrane repair was
accompanied by significant amelioration of behavioral deficits, including a delay in the emergence of motor deficits, a
delay of the emergence of peak symptom, and a reduction in the severity of peak symptom.
Conclusions: The current study is the first indication that axonal membrane disruption may be an important part of
the pathology in EAE mice and may underlies behavioral deficits. Our study also presents the initial observation that
PEG may be a therapeutic agent that can repair axolemma, arrest axonal degeneration and reduce motor deficits in
EAE mice.
Keywords: Multiple sclerosis, EAE, Axonal membrane damage, Polyethylene glycol, Acrolein, Horseradish Peroxidase,
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Background
Although inflammation is known to be the major
pathology of multiple sclerosis (MS), the mechanisms
underlying tissue damage and functional loss remain
unclear [1, 2]. While myelin degeneration has long
been considered the primary neuropathological char-
acteristic for MS, recent studies indicate that axonal
degeneration is also an important component of the path-
ology [3–5]. In fact, there is strong evidence suggesting
that MS is a neurodegenerative diseases [3, 6–8]. Indeed,
the integrities of both myelin and axons are indispensable
for neuronal function and survival [9]. Therefore, either
myelin or axonal damage could theoretically lead to
axonal conduction loss and degeneration seen in MS
[10–13]. Consistent with this notion, it has been sug-
gested that axonal disruption may represent irrevers-
ible neurodegeneration in patients with MS [3]. This
may in part explain why conventional strategies fo-
cusing solely on myelin protection have resulted in
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few effective treatments to slow or prevent MS pro-
gression [1].
Despite its potential importance in MS, axonal damage
has attracted significantly less attention compared to myelin
damage while both are known to lead to neurodegeneration
in MS [6, 7, 14]. Consequently, the pathological role of
axonal damage in MS remains insufficiently characterized.
Specifically, the key cellular processes that trigger axonal
degeneration remain unclear. We have previously shown
that axonal membrane damage contributes to axonal de-
generation observed in CNS trauma [11–13, 15–17]. We
have also shown that acrolein, a pro-inflammatory alde-
hyde that is capable of inflicting axonal membrane
damage and functional loss [18–24], is elevated and
likely plays an important pathological role in MS [25].
In light of this evidence, we speculate that damage to
the axonal membrane, or axolemma, likely leads to
neuronal degeneration and loss of neurological func-
tion, and therefore contributes to the development and
progression of symptoms observed in MS.
Polyethylene glycol (PEG), a hydrophilic polymer, is
well known for its ability to seal neuronal membranes
and consequently restore integrity and associated neur-
onal function [13, 26–29]. In particular, it has been
shown that PEG is capable of repairing axolemmal dam-
age and provide neuroprotection in traumatic spinal
cord injury [19, 26–28, 30–40]. However, the therapeutic
effect of PEG has not been examined in non-traumatic
CNS illnesses, such as MS, in which axonal membrane
damage likely plays a role leading to axonal degeneration.
Therefore, the primary focus of this study was to deter-
mine whether axolemmal disruption can be detected and
to examine its possible correlation with functional deficits
associated with MS. Subsequently, we also aimed to con-
firm the pathological role of axolemmal disruption in MS
and to assess the therapeutic efficacy of administering
PEG as a membrane sealant.
Methods
Experimental autoimmune encephalomyelitis mice
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of animals
were followed during the course of this research. Female
C57BL/6 mice were purchased from Harlan Laboratories
(Indianapolis, IN, USA) and were housed in the Purdue
University veterinary animal housing facilities. Ten to
twelve week old mice received two subcutaneous injec-
tions of 0.1 mL myelin oligodendrocyte glycoprotein/
complete Freud’s adjuvant emulsion (EK-0115, Hooke
Laboratories, Lawrence, MA, USA) into the upper and
lower back. Immediately following the emulsion injec-
tions, 0.1 mL of pertussis toxin (EK-0115, Hook
Laboratories) was administered intraperitoneally to the
mice, and again 22–26 h later. Behavioral assessment
was performed using a 5-point scale [41]. Animals were
placed on a metal grate to record their walking ability
and motor function. The behavioral scale used was as
follows: 0 – no deficit; 1 – limp tail only; 2 – hind limb
paresis without frank leg dragging; 3 – partial hind limb
weakness with one or both legs dragging; 4 – complete
hind limb paralysis; 5 – moribund, paralysis in hind
limbs and forelimbs. These studies were approved by
the Purdue Animal Care and Use Committee, Purdue
University, West Lafayette, IN.
Horseradish peroxidase exclusion test
The mice were separated into 4 groups: healthy control
mice, EAE mice before the onset of symptoms (pre-
symptom), EAE mice at peak behavioral deficit (peak
symptoms), and PEG-treated EAE mice. After confirm-
ation of behavior at various pre-determined experimen-
tal end points (Fig. 1), each group of animals was
anesthetized with Ketamine (90 mg/kg) and Xylazine
(10 mg/kg) and perfused (intra-cardiac) with a cold, oxy-
genated Krebs solution. The spinal columns were quickly
removed from the animal and a complete laminectomy
was performed. The spinal cord was then excised from
the vertebrae and placed in cold, oxygenated Krebs solu-
tion containing 0.015% horseradish peroxidase (Sigma
Fig. 1 Experimental design and time course. Diagram illustrates the
time course of the overall experiment related to EAE, pre-symptom
(EAE) and peak symptom (both EAE and EAE + PEG-treated) groups.
In addition, the time points when the HRP-exclusion assay was
conducted are illustrated: at pre-symptom (day 8 post-induction)
and at peak symptom (Day 28 post-induction), with or without PEG
treatment. Behavioral analysis was conducted daily and the average
time of onset of symptoms, and the average time of reaching peak
symptoms for both the EAE and the EAE + PEG group are illustrated.
In the EAE + PEG group, PEG treatment was carried out for the entire
period of study starting on the day of induction, as indicated in the
diagram. Tissue samples for HRP testing were extracted for 4 different
groups: healthy controls, pre-symptom EAE mice, peak symptom EAE
mice and PEG-treated EAE mice
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Type IV, Sigma Aldrich) for 2 h. The tissue was then
fixed in 2.5% glutaraldehyde in phosphate buffer for
4 h at room temperature. After fixation, a Vibratome
(Electron Microscopy Science, Hatfield, PA, USA) was
used to cut 30 μm transverse sections of the tissue. Tissue
was then processed in a diaminobenzidene solution to
visualize HRP uptake by damaged. Digital images of HRP-
stained spinal cord sections were obtained with an optical
microscope connected to a computer. Stained axons were
counted and expressed as density (axons/mm2) using
Image J analysis [15, 17, 30]. Animals were sacrificed for
structural analysis at pre-induction (control), 8 days post-
induction (pre-symptom), or 4 weeks post-induction (peak
symptom).
Polyethylene glycol treatment
Polyethylene glycol (295906, Sigma Aldrich, St. Louis,
MO, USA) was prepared as a 30% (w/v) solution in
phosphate buffered saline. The solution was then filtered
for sterilization and injected into each animal every day
after induction for the whole study (4 weeks post-
induction). A volume of 0.1 mL was administered intra-
peritoneally daily after induction for the duration of the
study. EAE only animals were administered the same
amount of saline rather than PEG.
Statistical analysis
Throughout the paper, Mann Whitney U test was used
to compare the difference of the severity of motor de-
fects, the onset of motor deficits, and the onset of peak
symptoms between EAE and EAE + PEG-treated groups.
Kruskal-Wallis test was used for comparison of mem-
brane permeability assessed by HRP-exclusion test in
various groups. The statistical significance level was set
at p < 0.05. All data are expressed as mean ± standard
error of the mean (SEM).
Results
Significant axonal membrane damage in EAE mouse and
its reduction by Polyethylene glycol
Using an EAE mouse model, we first examined axonal
membrane damage using a well-established HRP-exclusion
assay. The integrity of axonal membrane from the spinal
cord of control mice, EAE mice before the onset of symp-
toms (pre-symptom), and EAE mice at peak behavioral
deficit (peak symptom) was examined (Fig. 1). We have
found that the average HRP labeling for these conditions
was 811 ± 130 axons/mm2, 3293 ± 500 axons/mm2, and
6147 ± 655 axons/mm2 respectively (Fig. 2). EAE mice at
peak deficit demonstrated significantly higher levels of
HRP labeling compared to control mice (P < 0.01).
Interestingly, pre-symptom EAE mice also displayed
increased axonal membrane permeability compared to
control mice (P < 0.05).
We further examined the possibility that PEG can re-
duce axonal membrane permeability. Specifically, EAE
mice were given daily injections of 0.1 mL of either poly-
ethylene glycol (30% w/v) (EAE + PEG), or saline (EAE
only) beginning on the first day of induction and then
daily for 4 weeks (Fig. 1). Axonal integrity based on the
HRP exclusion assay was carried out at the end of the
treatment period. We have found that the density of
HRP-labeled axons in the EAE-PEG treated group was
1581 ± 247 axons/mm2, which is significantly lower than
that of the EAE only mice at peak deficit (6147 ± 655
axons/mm2, p < 0.01) (Fig. 2).
Polyethylene glycol temporally ameliorates motor deficits
in EAE mice
In addition to axonal membrane permeability examination,
we also carried out behavioral analysis in two experimental
groups, EAE and EAE + PEG mice. The behavioral observa-
tion for each animal was recorded daily on a 5-point scale
immediately following induction and continuously for
4 weeks. The average behavioral score was calculated for
each day in two groups and displayed over time in Fig. 3.
The severity of behavioral deficit in the EAE/PEG-treated
group was significantly lower than the EAE group during
the period of day 16 to 25 days post EAE induction. When
averaging the highest scores of each animal within
each group, the PEG-treated EAE mice (1.91 ± 0.4)
displayed a significantly lower score than the EAE mice
(3.33 ± 0.3, P < 0.05) (Fig. 3 upper inset). In addition, PEG
treatment also significantly delayed the time of reaching
peak symptoms (23.1 ± 1.6 days for EAE-PEG, and 18.7 ±
0.8 days for EAE group, P < 0.05) (Fig. 3 lower inset).
In addition to decreased peak symptom severity and
delayed time to reach the peak symptom, PEG treated ani-
mals also showed delayed symptom onset as depicted in
Fig. 4. Specifically, in the EAE group, all mice began to
display their behavioral deficit between days 13 and 18. In
contrast, the EAE + PEG group revealed a more dispersed
result with a trend of delayed onset. Specifically, five EAE
+ PEG animals began exhibiting symptoms at approxi-
mately the same time as the EAE group (13–18 days
induction) while the others were later in time: three exhib-
ited no observable behavioral deficit throughout the 4-
week observation (counted as day 28 when averaging)
while the remaining three mice showed their first motor
defects at between day 20–26 post induction. Overall,
the average day of onset for EAE mice that received
PEG-treatment was 20.63 ± 1.8 days which is signifi-
cantly delayed compared to EAE mice (15.42 ± 0.4 days,
P < 0.01) (Fig. 4).
Discussion
Based on the current study using the HRP-exclusion
assay, a well-established method of assessing axonal
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membrane permeability [11, 13, 15–17, 30, 42], we have
determined that there is a significant level of axonal
membrane disruption in EAE mice when symptoms
peak. In addition, we also noted a prominent increase,
although at a lesser degree, of axonal membrane damage
in the pre-symptom stage in EAE mice (Fig. 2). To our
knowledge, this is the first evidence of axonal membrane
damage in EAE mice, an animal model MS.
Furthermore, PEG, a known membrane repairing
agent [28–31], when applied daily for 4 weeks after in-
duction, can significantly reduce axonal membrane dis-
ruption in EAE mice (Fig. 2). The restoration of axonal
membrane integrity by PEG was accompanied by signifi-
cant amelioration of behavioral deficits, including a
delay of the onset of motor deficits typical of EAE, a
delay of emergence of peak symptom, and a reduction of
peak symptom severity (Figs. 3 and 4). Taken together,
we have presented initial evidence that axonal mem-
brane disruption is an important feature of the overall
pathology in EAE mice that is at least in part responsible
for the behavioral deficits. Our study also presents the
first indication that PEG could be used as a therapeutic
agent to effectively repair axolemma, arrest axonal de-
generation and reduce motor deficits in EAE mice.
Although not examined in this study, it is likely that
PEG-mediated axonal membrane repair also leads to the
reduction of axonal degeneration, a known pathology of
MS [3, 4, 43]. It is well known that axonal membrane
disruption, if not repaired, will lead to axonal degener-
ation, neuronal cell death and overall neuronal tissue
degeneration [13, 17, 44–46]. It has also been demon-
strated repeatedly that PEG-mediated neuronal mem-
brane repair can lead to the reduction of oxidative stress
and mitochondrial dysfunction which are known con-
tributors to axonal degeneration and neuronal cell death
[19, 26, 29, 35, 47]. As such, PEG may also provide neu-
roprotection by indirectly suppressing oxidative stress
and inflammation. Therefore, we postulate that PEG-
mediated membrane repair can mitigate axonal degener-
ation and could promote a range of cellular functions
that lead to the improvement of motor function in EAE
mice.
Although we did not confirm the presence of PEG in-
side the spinal cord in the current study following
Fig. 2 Membrane permeability assessed by HRP-exclusion test. Horseradish peroxidase (HRP)-exclusion test determined amount of axonal membrane
damage in healthy control mice (n = 5), pre-symptom EAE mice (n = 7), peak symptom EAE mice (n = 6), and peak symptom EAE + PEG-treated mice
(n = 7). For pre-symptom EAE group, samples were taken at 8 days post-induction, before symptom emerges. The samples of peak symptom group
(for both EAE and EAE + PEG-treated) were taken at 28 days post-induction. a–d The images represent HRP-stained sections of spinal cord tissue from
the four groups. Solid arrows denote areas in which HRP did not penetrate the cell while the open arrows point to areas depicting HRP penetration
revealing increased axonal membrane permeability. e The bar graph quantifies HRP uptake in each group. The average density for the control group
was 811 ± 130 axons/mm2. The peak symptom group had the highest levels of axonal damage (6147 ± 665 axons/mm2, ** P < 0.01 compared to
control) while the pre-symptom group exhibited increased levels compared to the control group (3293 ± 500 axons/mm2, * P < 0.05 compared to
control). In addition, HRP labeling in the EAE/PEG-treated group (1581 ± 247 axons/mm2) is significantly lower than EAE group (** p < 0.01). Scale
bar = 10 mm for a, b, c and d
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systemic application, we believe the main location of PEG
treatment is in the central nervous system (CNS), particu-
larly in spinal cord. This is because we have detected
significant membrane repair in spinal cord when PEG was
applied comparing to no PEG (Fig. 2), and PEG is known
to be able to reach spinal cord following systemic applica-
tion [48]. It is unlikely that PEG-mediated neuroprotec-
tion is due to peripheral effects, considering the main
pathology of EAE is in CNS [2].
Despite the strong evidence of severe axonal membrane
damage in EAE, the mechanisms of such axolemmal dam-
age remain to be elucidated. Based on the previous studies
from our and other labs, we suggest that acrolein, a lipid
peroxidation byproduct, may be one of the culprits. In a
recent study from our lab it was shown that acrolein was
increased significantly in EAE mice [25]. We have also
shown that acrolein can cause membrane disruption in
various preparations at levels that are likely achievable in
in vivo pathological conditions [20–22, 49–51]. In fact,
acrolein has been suggested to cause neuronal damage in
trauma by disrupting neuronal membrane through a de-
layed mechanism [24, 49, 50, 52–54]. In light of this evi-
dence, we hypothesize that acrolein may play a role in
axonal membrane disruption in EAE mice. One critical
piece of evidence supports this hypothesis is that hydral-
azine, an effective acrolein scavenger, can lower acrolein
levels and reduce motor deficits in EAE mice [25]. In
addition, a recent study from our group demonstrated
that acrolein-mediated axonal conduction loss can be
partially mitigated by a potassium channel blocker, indi-
cating a concomitant acrolein-mediated myelin damage in
addition to axonal lesions [24]. This is because augmented
potassium channel activity is a known consequence of
myelin damage in injured axons [55]. Consistent with
such notion, we also have found that acrolein trapping
treatment was associated with restoration of neuronal
membrane integrity, reduced neurodegeneration and en-
hanced functional recovery in traumatic spinal cord injury
[21, 22, 24, 50, 51, 53]. It will be interesting to confirm the
likely scenario that anti-acrolein therapy alone could lead
to the preservation or restoration of axonal membrane
integrity in EAE.
In the current study, in addition to the severe mem-
brane disruption observed when symptoms peak, we also
noted a less severe, yet still significant level of membrane
disruption, and therefore neurodegeneration, in the pre-
symptom period defined as a week prior to the emergence
of motor deficits (Figs. 1 and 2). Therefore, significant
Fig. 3 PEG ameliorated the severity of motor defects and delayed the time of reaching peak motor deficits. Comparison of behavioral assessment
each day between EAE (saline-treated, n = 12) and EAE + PEG (EAE-treated with PEG, n = 11) groups. The graph represents the average score for
each group of animals throughout the study. The upper inset demonstrates that administration of PEG significantly decreased the peak symptom
severity in EAE mice (P < 0.05). The highest score of each animal was recorded and averaged within each group to quantify the mean score of
severity to be used for the upper inset. As indicated, the average of the peak EAE score in EAE + PEG group (1.91 ± 0.4) is significantly lower than
that in EAE group (3.33 ± 0.3, P< 0.05). The lower inset describes the average time of reaching peak symptom of motor deficits in both EAE and EAE + PEG
groups. For both EAE and EAE-PEG group, the time of reaching peak symptom is defined as the time that the most severe symptom, or the highest EAE
score (≥2) first appears for each animal. If an EAE score of 2 is never reached during the experimental duration (28 days), then 28 day is used as the time
of reaching peak symptom. As shown, the average time of reaching the peak EAE score in EAE + PEG group (23.1 ± 1.6) is significantly longer than that in
EAE group (18.7 ± 0.8, P< 0.05)
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level of membrane damage and neurodegeneration appear
to already exist in the pre-symptom period while no con-
comitant noticeable behavioral deficits were detected. This
phenomenon may be explained by the fact that there is a
significant amount of implicit redundancy of axons to
support neuronal function. Therefore, there is likely a
threshold level of axonal damage and neurodegeneration
that must be reached before observing behavioral changes.
This would justify the notion that membrane damage
could start before the onset of behavioral deficits and that
the emergence of behavioral deficits signifies a critical
level of axonal damage and degeneration. Hence, the ini-
tial membrane damage could theoretically serve as an
indication to predict the onset of behavioral deficits at a
later date.
In light of these observations related to the relationship
between axonal membrane damage and behavioral per-
formance, we suggest that axonal membrane damage in
MS could serve as an important diagnostic measurement.
First, it can potentially be used as a biomarker for the de-
tection of MS before the emergence of symptoms. This
could help to institute earlier treatments to deter neurode-
generation for better therapeutic outcomes provided that
the pre-symptomatic axonal membrane damage can be
firmly identified. Second, axonal membrane integrity
could also serve as an indication of the effectiveness of
membrane repair therapy such as PEG. Such a strategy is
understandably dependent on development of a reliable
non-invasive imaging method to detect axonal membrane
disruption or degeneration.
It has become increasingly clear that, in addition to
myelin damage, axonal degeneration may also play a
critical role in EAE pathology. From a basic cellular
biology view, the integrity of both myelin and the axonal
membrane are essential for axonal conduction. There-
fore, axonal degeneration along with myelin damage, are
likely to be equally important contributing factors in
axonal conduction failure and behavioral deficits in EAE
mice [5, 12, 15, 17, 54, 56, 57]. The current study further
highlighted the critical role of axonal damage, and axo-
lemmal disruption in particular, in neurodegeneration
and the functional loss in MS. To further stress the im-
portance of axonal degeneration in MS, there is evidence
that axonal damage and neurodegeneration may be the
main cause of functional loss without obvious myelin
damage in some human case of MS. For example, based
on a histopathologic investigation using autopsy tissue
from MS patients, Trapp and his colleagues have shown
compelling evidence of axonal degeneration in the ab-
sence of myelin loss [43]. Therefore, axonal damage, a
key feature of neurodegeneration, may not just be one of
the important compounding pathological factors, but ra-
ther it may be among the primary and critical factors
that are sufficient to cause clinical functional deficits in
MS. To further highlight the importance and causal role
of axonal damage in MS pathology, we have noted a sig-
nificantly higher susceptibility of acrolein-mediated
axonal damage compared to acrolein-mediated myelin
damage. Specifically, Shi and his colleagues have found
that using an ex vivo preparation of extracted rodent
spinal cord segment, the threshold of acrolein needed to
inflict membrane damage is two magnitudes lower than
that needed to cause significant myelin damage [10, 49].
This suggests that in MS patients, axonal degeneration
may be, in some cases, the primary pathology that pre-
cedes myelin damage. Furthermore, due to the existing
Fig. 4 PEG delayed the onset of motor deficits. Comparison of onset of symptoms between EAE (saline-treated, n = 12) and EAE + PEG (EAE-treated
with PEG, n = 11) groups. The graph represents the temporal distribution or symptom onset for EAE and EAE + PEG mice. The number of mice
showing initial symptoms was recorded daily for each group. Symptom onset for EAE mice was tightly clustered early in the study while onset for EAE
+ PEG mice was more dispersed. The inset graph represents the average day of onset for EAE and EAE + PEG groups. Animals in EAE + PEG group
developed symptoms significantly later in the study compared to EAE mice (P < 0.01). Three mice in the EAE + PEG-group never developed symptoms
and were counted as day 28 for both graphs
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evidence of damaging both axon and myelin, acrolein may
be a critical link for the damage of both myelin and axons,
two known pathologies in EAE. This hypothesis is sup-
ported by the factor that acrolein scavenging could miti-
gate the damage of both myelin and axons [25, 26, 29].
The emergence of the importance of axonal damage as
the critical pathology warrants closer examination of our
existing therapeutic strategies as well as our efforts to
establish new therapies. It appears reasonable to suggest
that a treatment regimen should include axonal repair
and protection in addition to myelin protection. This
combination of treatments may be a synergistic treat-
ment strategy and could result in increased efficacy. We
have previously shown that both anti-acrolein (by hy-
dralazine) and membrane repair (by PEG), when used
alone, can offer significant, albeit partial alleviation of
behavioral deficits [25] (Fig. 3). Furthermore, though
PEG significantly delayed the onset and reduced severity
in most of the symptomatic periods, such symptom
reduction was temporary. PEG treatment did not lead to
significant behavioral improvement beyond 26 days post
induction, despite effective sealing of the axonal membrane.
Therefore, it appears that PEG-mediated membrane repair
alone cannot offer long-term symptom reduction. This
could be the case for at least two reasons. First, this may
indicate that membrane repair strategies need to be com-
bined with approaches that remove causes of cellular dam-
age, such as acrolein, to ultimately protect the cell. Second,
although a proven axonal membrane repair agent, PEG has
not been shown to also repair myelin damage.
Conclusions
Our findings demonstrate that there is significant axonal
membrane damage in addition to myelin destruction and
both likley contribute to neurodegeneration in EAE mice.
Further, the impairment of axon and myelin may require
distinct protective measures and both are critical for
a normalization of neuronal function. Taken together,
PEG-mediated membrane repair strategy may need to
be combined with other measures designed to protect
and repair myelin in order to maximize the thera-
peutic effect and ultimate functional preservation and
recovery in MS.
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